


PRA International **Therapeutic Experts in Oncology**

PRA's Scientific and Medical Affairs group provides highly focused, expert leadership in the design and implementation of drug development programs. PRA is a proven leader in oncology clinical drug development, with extensive involvement in the successful approval of major, life-extending cancer drugs.

*The following biographies detail the experience and credentials of several of **PRA's Therapeutic Experts in Oncology.***

John Constant, PhD

VP, Scientific Affairs



Dr. Constant has over 20 years experience in applied statistics and over 15 years in pharmaceutical research. He has served on Data Monitoring,

Steering and Advisory Committees and as statistical advisor in oncology to various biotechnology and pharmaceutical companies. He has also served as a liaison to the FDA and EMEA on their behalf, having worked in that capacity with numerous heads at the Agencies. Dr. Constant has also provided statistical consulting services to clients for oncology submissions in response to ODAC feedback, and he has voted on, organized and written charters for many DMCs for numerous oncology studies. His oncology area experience includes design, analysis, reporting and regulatory agency representation on national and global trials and submissions in lung cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, myeloma, lymphoma, melanoma, kidney cancer, liver cancer, bladder cancer, brain cancer and head and neck cancer.

Ute Berger, MD

VP, Medical Affairs
Europe, Africa, and Asia-Pacific



Dr. Berger is board-certified in Internal Medicine, Hematology and Medical Oncology, with special expertise in leukemias and lymphomas.

Dr. Berger received her MD from the University of Heidelberg, and has served in senior positions on the Faculty of Clinical Medicine Mannheim, University of Heidelberg. She has extensive experience in clinical trials and over 18 years of clinical experience in academia. She is also certified by the European Society of Medical Oncology (ESMO). She has held numerous prestigious professional positions, including serving as the medical coordinator for the German CML Study Center, General Manager of the German Competence Network "Acute and Chronic Leukemias," and as Scientific Network Manager of the "European LeukemiaNet," as well as a board member of the Telematikplattform eV, a platform for medical research networks. Dr. Berger has particular expertise and a strong interest in clinical research in hematology and oncology, and has published extensively in prominent journals. She also possesses close contact with many therapeutic experts and investigative sites in the fields of hematology and oncology, and is able to offer a uniquely-informed perspective in oncology research.

Kent Thaelke

Head and Senior VP, Scientific and Medical Affairs



Kent Thaelke is a highly trained global drug development professional with over 15 years of experience in all aspects of the global drug development

and device industry. He has extensive experience in the conduct of global Oncology studies and spent six years leading the Oncology drug development efforts of a large CRO prior to joining PRA. He has a comprehensive understanding of all stages of product development for oncology, including regulatory, manufacturing, CMC, preclinical and clinical aspects. He is currently listed as an inventor on 10 patents related to a multiple myeloma therapy, and spent four years dedicated to the development of an investigational drug for multiple myeloma seeing it through Phases I to III. Additionally, Mr. Thaelke is well-published in multiple myeloma, having co-authored numerous related articles as well as presented at the International Myeloma conference in Stockholm. Having visited oncology sites in over 35 countries, Mr. Thaelke is also very familiar with the global oncology environment and has established relationships with therapeutic experts in numerous oncology indications around the world.



Dr. Robert Shepard, MD, FACP

VP, Therapeutic Unit Oncology and Hematology



Dr. Shepard is board-certified in oncology, hematology, and internal medicine, and has a strong background in immunology and molecular

genetics. He graduated Magna cum Laude in Biochemical Sciences and Molecular Biophysics from Harvard College, and earned his MD degree in the Medical Scientist Training Program at Duke University. Prior to joining PRA, Dr. Shepard headed the Oncology and Hematology development program for a major CRO and was responsible for the complete clinical development of several cancer drugs and immune therapies. Additionally, he has conducted phase I oncology studies in both community and academic oncology settings, and was in charge of phase I studies and developmental therapeutics for close to four years while at the University of Virginia Cancer Center. Dr. Shepard also worked as a Medical Officer in Cancer Biologics Evaluation and Research at the FDA, and he has extensive experience in clinical research in community hematology and oncology as well as academia, having taught at Harvard, Tufts, Johns Hopkins, and the University of Virginia.

He is a member of several professional societies including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society of Hematology, and the European Society for Medical Oncology, and has published over 30 papers on relevant topics.

Tariq Parvez, MD, BSc, MBBS

Medical Director- Oncology



Dr. Parvez is a clinical oncologist with 31 years of experience as a medical doctor engaged in patient care. He has spent more than 21

years involved in clinical oncology and in oncology patient management and care, with 13 of those years as the head of various oncology departments. He most recently served as a consulting oncologist at a major medical center in Saudi Arabia, prior to which he spent 11 years as the resident clinical oncologist and head of Radiotherapy/Oncology at two major hospitals in Pakistan. Currently, he acts as a Medical Director at PRA for multiple oncology clinical trials. Areas of expertise include, but are not limited to, solid tumors, lymphoma and supportive care. Dr. Parvez is Chairman and Founder of the Pakistan Society for Cancer Prevention and Pakistan Ostomy Society. He is also a life member of the Pakistan Society for Clinical Oncology, the Pakistan Radiological Society, and the American Society for Clinical Oncology. He has written and contributed to eight books and several hundred articles on oncology-related topics. Furthermore, Dr. Parvez has been the recipient of numerous awards including the President of Pakistan Gold Medal Award for Research and Publications as a result of his strong interest and advocacy in oncology research.

Violetta Laszczewska, MD, PhD

Senior Medical Director, Oncology



Dr. Laszczewska is board certified in Internal Medicine, Chemotherapy of Cancers, and Clinical Oncology. She received her medical degree

from the Medical University in Lodz, Poland, and has a PhD in Medical Science. Dr. Laszczewska completed a specialized internship in the Internal & Hematology Department of the Medical University Hospital in Warsaw and specialized internship in oncology in Oncology Center Institute in Warsaw. Since joining PRA in 2002, she has been involved in oncology, ophthalmology, and rheumatology clinical trials as a CRA and as a Medical Director of Oncology. As a Medical Director she has worked in nearly every oncology indication. Before joining PRA, she worked for nine years as an Oncologist in the Oncology & Urology Department of the M. Skłodowska – Curie Memorial Oncology Centre Institute in Warsaw. Dr. Laszczewska is a member of Polish Society of Oncology.

Philippe Chahinian, MD

Medical Director, Therapeutic Expertise



Board certified in Internal Medicine and Oncology, Dr. Chahinian graduated from Paris University Medical School in France and completed

an Oncology Fellowship at the Mount Sinai Medical Center in New York. He has held positions as a professor and attending physician within the Division of Medical Oncology since 1976 at the Mount Sinai Medical School, with a four year hiatus to act as Chief of Oncology and Director of the Cancer Center at St. Luke's/Roosevelt Hospital Center in New York. Dr. Chahinian has conducted many phase I, II, and III clinical studies in oncology. He has particular experience in research in thoracic oncology, including lung cancer, mesothelioma, and thymic tumors. Dr. Chahinian has been a member of cooperative groups including the European Organization for the Research and Treatment of Cancer (EORTC) and CALGB, and has published over 100 medical articles in peer-reviewed journals, and has authored more than 40 chapters for medical textbooks. Additionally, he conducted laboratory research based on mesothelioma xenografts in athymic mice, for which he was awarded a grant from the US National Cancer Institute.

Valery Novikov, MD, PhD

Director of Operations



Dr. Novikov is a clinical oncologist and holds a PhD in clinical investigation of new medicine. He has significant experience in chemotherapy,

endocrine therapies, biologic response modifiers, radiation and supportive care. He was trained at the Hematological center and Cancer Research Center of Moscow, the largest and most advanced cancer institution in Russia and the former USSR. He has worked for PRA as the Director of Operations (Russia) since 2003, has been an Investigator on numerous trials, (breast, colon, stomach, sarcoma and ovary) and led several projects as coordinator and clinical monitor in Russia and Ukraine prior to joining PRA. He has broad therapeutic experience in all phases of drug development including oncology (phases I-III), hematology (phases II-III), cardiology (phase III), rheumatology (phases II-III), osteoporosis (phases II-III), blood substitution (phases II-III), hemophilia (phases II-III), and gynecology (phase III).

Beata Paluchowska, MD, PhD

Medical Director – Oncology



Dr. Paluchowska is board certified in internal medicine, clinical oncology, and chemotherapy of cancers. She received her MD from the Warsaw Medical School,

Poland, and has a PhD in medical science. Dr. Paluchowska did her post-graduate training at Central Clinical Hospital, Warsaw, and did her internal medicine specialization training at the Center of Post-Graduate Education, Warsaw. She has over ten years of clinical experience at the M. Sklodowska- Curie Memorial Oncology Centre Institute, Warsaw and has been involved in many clinical trials in the fields of kidney, urothelial, testicular, prostate and penile cancers and supportive treatment. She was a participating member of the Genito-Urinary Group of the European Organisation for Research and Treatment of Cancer (EORTC) and is a member of the Polish Society of Clinical Oncology and European Association of Urology. She has published more than 20 original articles in peer-reviewed international journals and has conducted numerous congress presentations. Dr. Paluchowska has been with PRA International since 2004, most recently as a Medical Director II. During this period she has been involved in clinical studies in the fields of breast, ovarian, and lung cancer, as well as AML and several Phase I trials.





Proven Therapeutic Leadership

PRA's experts in oncology have extensive experience in designing and managing both individual study protocols and complete clinical development programs. We provided the developers of such important cancer treatments as Sutent®, Nexavar®, Avastin®, Tarceva® and Velcade® with the full range of development and research services to accelerate their products to market.

As a leader in oncology, PRA has significant experience in many indications, with considerable expertise in non-small cell lung cancer, colorectal cancer, breast cancer and renal cell cancer.



PRA International

THE GRO THAT UNDERSTANDS ENDPOINTS ■

4141 ParkLake Avenue, Suite 530

Raleigh, NC 27612 USA

Tel: +1 919 786-8200 Fax: +1 919 786-8201

To learn more, e-mail us at endpoints@praintl.com

or visit www.prainternational.com

